Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Laurie Keating is Director at Immuneering. OQRO lists 3 transactions filed with the SEC under this name, the latest on Aug 3, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
Aug 1, 202618Kdisclosed Aug 3
DetailsOfficial recordImmuneeringIMRX
2 disclosures · Jan 2026 – Jun 2026
Jun 11, 202633K
Jan 1, 20267,888disclosed Jan 2
DetailsOfficial recordLaurie Keating bought shares on the open market in 2017, 2021 and 2022, and has not bought since 2022 across 3 companies. Sales in 4 of the 10 years since 2017.
In SEC filings since 2017: the latest open-market purchase is from 2022; the latest open-market sale is from 2021.
3 companies: Immuneering (IMRX, 2021–2022), Pepgen (PEPG, 2022), Alnylam Pharmaceuticals (ALNY, 2017–2021).
Laurie Keating bought shares on the open market in 2017, 2021 and 2022, and has not bought since 2022 across 3 companies. Sales in 4 of the 10 years since 2017.
Laurie Keating reported 4 open-market purchases and 41 sales since 2017; purchases in 3 different years, most recently 2022.
| Year | Bought | Sold |
|---|---|---|
| 2022 | $85K2×2 trades | — |
| 2021 | $105K1×1 trade | $7.42M10×10 trades |
| 2020 | — | $15.9M15×15 trades |
| 2018 | — | $3.3M8×8 trades |
| 2017 | $752K1×1 trade | $4.83M8×8 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Laurie Keating reported 1 open-market purchase and 41 sales here, 2017 to 2021.
Laurie Keating reported 2 open-market purchases and 0 sales here, 2021 to 2022.
Laurie Keating reported 1 open-market purchase and 0 sales here, 2022.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.